Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: J Allergy Clin Immunol. 2017 Jun 9;140(4):1202–1206.e3. doi: 10.1016/j.jaci.2017.03.052

Figure 2. Using fluorochrome-labelled avidin to monitor the status of basophil activation in whole blood of peanut allergic patients.

Figure 2

(A) Protocol for assessing basophil activation by flow cytometry in whole blood.8 (B) Representative dot plot of HLA-DR−CD123+ basophils incubated with RPMI, anti-IgE or peanut flour and stained with anti-CD63-FITC or Av.A488. (C) Percentage of CD63+ (black) or Av.A488+ (green) basophils after RPMI or anti-IgE or peanut extract challenge in 41 peanut allergic patients. Lower/higher 5% values are plotted as individual dots. Boxes extend from the 25th to 75th percentiles and whiskers represent 5th and 95th percentiles. Bars indicate medians. (D) Comparison of CD63+ (black) or Av.A488+ (green) basophils after RPMI (left) or anti-IgE (right) for each patient. Linked dots represent results from the individual patients. (E) Percentage of Av.A488+ basophils in 19 anonymous donors (open) versus 41 peanut allergic patients (black). (F) Y axis: Percentage of Av.A488+ basophils after RPMI (baseline) incubation in 14 peanut allergic patients in the POISED oral immunotherapy (OIT) trial that were challenged with increasing amounts of peanut flour; X axis: amount of tolerated peanut flour (mg) as per Bock’s criteria.9 Mean + SEM; Mann-Whitney U tests; ***P < .0005; **P < .005; *P < .05.